Conduct of the Trial Sample Clauses

Conduct of the Trial. 2.1 UCL and CTC shall undertake the Trial as Sponsor according to the approved Protocol, the Regulations, GCP and any other applicable local laws and regulations.
AutoNDA by SimpleDocs
Conduct of the Trial. 1.1 The INSTITUTION and INVESTIGATOR each agree to perform the clinical trial in strict accordance with the protocol entitled, “ .” STUDY, dated 29 May 2014, which vlastní know-how a technické informace o takových produktech a prostředcích. VZHLEDEM K TOMU, ŽE ZADAVATEL najalklinickou výzkumnou organizaci Pharmaceutical Research Associates International („CRO”), aby jednala jako nezávislý dodavatel, ale ne jako strana této SMLOUVY, jménem ZADAVATELE za účelem provedení určitých aspektů úkolů ZADAVATELE uvedených níže, jako například splnění SMLOUVY, zaplacení, monitorování a/nebo jiné činnosti v rámci STUDIE; a VZHLEDEM K TOMU, ŽE společnost UCB BIOSCIENCES, INC. je jmenována ZADAVATELEM STUDIE (jak je definováno níže) a delegovala odpovědnost za provádění takové STUDIE na svoji SESTERSKOU SPOLEČNOST UCB BIOSCIENCES GMBH která xx xxxx označována jako ZADAVATEL pro účely této SMLOUVY; a VZHLEDEM K TOMU, ŽE si ZADAVATELpřeje zmocnit INSTITUCI k organizování a provedení („STUDOVANÝ LÉK“). („STUDIE“); a VZHLEDEM K TOMU, ŽE ŘEŠITEL jezaměstnán INSTITUCÍ a bude působit jako ŘEŠITEL pro STUDII (definováno výše); a VZHLEDEM K TOMU, ŽE INSTITUCE aŘEŠITEL přezkoumali dostatečné množství informací týkajících se STUDOVANÉHO LÉKU a PROTOKOL (definováno níže) pro vyhodnocení jejich zájmu o účast na STUDII. PROTO NYNÍ STRANY v úmyslu být právně vázány uzavřely tuto SMLOUVU a domluvily se zvláště na následujícím: 1. PROVEDENÍ HODNOCENÍ 1.1 INSTITUCE a ŘEŠITEL se zavazují každý zvlášť provést klinické hodnocení v přísném souladu s protokolem pod názvem „“ STUDIE , ze dne 29 května
Conduct of the Trial. The Institution, through the applicable Principal Investigator and Sub- investigators, shall use reasonable efforts to conduct each Trial in accordance with this Agreement, the applicable SOW, the applicable Protocol, and the applicable investigator’s brochure for the Protocol (the “Investigator’s Brochure”), as each may be amended, and all applicable United States laws, rules, regulations and guidelines, as adopted into law relating to the conduct of clinical investigations, good clinical practice (GCP) principles, generally accepted medical practice, and applicable export control rules and regulations (collectively, “Applicable Laws”). For purposes of this Agreement, the term “Institution” shall include all employees, executives, officers, directors, faculty, staff and other authorized agents of the Institution. SPONSOR will use reasonable efforts to perform its applicable obligations in connection with each Trial including, but not limited to, monitoring visits. Initiation of a Protocol under a SOW shall not begin until IRB (defined in Section 6.2) approval is obtained. SPONSOR and Institution shall consider each Trial under a respective SOW to be complete and concluded at all sites at such time as the occurrence of final data lock or earlier termination by a Data Safety Monitoring Board (“Trial Conclusion”). Sponsor shall conduct its obligations under this Agreement and each Trial in accordance with Applicable Laws.
Conduct of the Trial. 2. Provádění studie.
Conduct of the Trial. The Sponsor and the CI shall undertake the Trial according to the approved Protocol, the Regulations, GCP (which, for clarity, refers to the principles of ICH Harmonised Tripartite Guideline for Good Clinical Practice (CPMP/ICH/135/95) as set out in Schedule 1 (Conditions and Principles of Good Clinical Practice and for the Protection of Clinical Trial Subjects) of the Medicines for Human Use (Clinical Trials) Regulations 2004 and the GCP Directive 2005/28/EC, as set out in SI 2006/1928, and any amendments thereto), and any local laws and regulations applicable to clinical trials and the care of clinical trial subjects. The Trial shall be conducted by the CI: In all participating site(s) selected by the CI, with Sponsor oversight of site feasibility requirements; In accordance with the approved Protocol and any amendment/ modifications to the Protocol (unless urgent safety measures are deemed necessary); In accordance with the terms of the clinical trial authorisation (CTA) granted by the regulatory authority (MHRA); In accordance with the terms and conditions of the [REC]/[GTAC](delete what is not applicable) approval given to the Trial; In accordance with the relevant safety reporting provisions, as further described in this Agreement and the approved Protocol. In accordance with the applicable Sponsor SOPs for CTIMPs as amended from time to time and available on the JRO web site. The Parties acknowledge that the CI is expected to comply with their obligations under this Agreement as of its effective date in accordance with clause 4.1. Notwithstanding the foregoing, the CI is expected to comply with as many obligations as possible if the Trial has been set up prior to the effective date of this Agreement. The Parties shall comply with all UK laws and statutes applicable to the performance of clinical trials including, but not limited to, the Human Rights Act 1998, the Data Protection Act 1998, The Freedom of Information Act 2000, EU Regulations on Advanced Therapy Medicinal Products (delete if not an ATMP Trial), The EU Tissues and Cell Directive (delete if not an ATMP Trial involving procurement of tissues or cells), The Human Tissue Act 2004, the Regulations (as previously defined), GMP (which, for clarity, refers to refers to European Commission Directive 2003/94/EC laying down the principles and guidelines of good manufacturing practice in respect of medicinal products for human use and investigational medicinal products for human use, and any amendm...
Conduct of the Trial. The parties shall conduct the Trial on or before the date agreed upon.
Conduct of the Trial. Institution shall, and shall cause Principal Investigator and all Institution Personnel to, diligently perform the Trial in accordance with (i) the Protocol, (ii) Applicable Law, (iii) Sponsor’s or its designee’s written instructions and (iv) Institution’s internal policies (which policies Institution represents and warrants are not inconsistent with any of the foregoing). For purposes of this Agreement, “Applicable Law” shall mean all applicable laws, rules, and regulations pertaining to the activities contemplated herein, including without limitation, Directive 2001/20/EC, as implemented in the Czech Republic and as replaced by the CTR as soon as applicable, and Regulation (EU) 2016/679 of 2.1
AutoNDA by SimpleDocs
Conduct of the Trial 

Related to Conduct of the Trial

  • Conduct of the Hearing The arbitrator shall hold the hearing in Portland, Oregon unless otherwise agreed to by the parties. The hearing shall commence within sixty (60) working days of the arbitrator's acceptance of the case, unless both parties agree to an extension of time. If the arbitrator or either party requests that post-hearing briefs be submitted, the arbitrator shall establish a date for the submission of such briefs and the hearing will be deemed to have been closed by such date.

  • Conduct of the Parties The parties will not engage in behaviour that is, or may reasonably be considered to be intimidating, bullying, or harassing or commit any act or behaviour which is offensive or abusive in connection with this Agreement.

  • Conduct of the Business From and after the Effective Date and though immediately prior to the Closing, or the earlier termination of this Agreement in accordance with Article 9, except (i) as set forth on Section 6.1 of the Disclosure Schedule, (ii) as otherwise contemplated by this Agreement, (iii) as Buyer or Parent may otherwise consent to in writing (which shall not be unreasonably withheld) or (iv) as required by applicable Legal Requirements, Seller will, and will cause each Acquired Subsidiary to (a) operate the Business in the Ordinary Course of Business and use commercially reasonable efforts to preserve and maintain the goodwill associated with the Business and relationships with the Employees, customers, suppliers, distributors and others with whom the Business has a business relationship and (b) not, without the consent of Parent, take any actions (i) that if taken between the date of the Latest Balance Sheet and the date hereof would be required to be disclosed on Section 4.5 of the Disclosure Schedule (ignoring the phrase “management level” in Section 4.5(k) for purposes of this Section 6.1); (ii) that would cause a Material Contract to be accelerated, terminated, modified, or cancelled by Seller or any Acquired Subsidiary, or that would cause the entry into any Material Contract by Seller or any Acquired Subsidiary (other than any purchase orders or sales or services agreements on the Business’s standard forms) that is outside the Ordinary Course of Business or that involves the payment or receipt by Seller or the Acquired Subsidiaries of more than $50,000; (iii) that would cause any Acquired Subsidiary to issue or otherwise allow to become outstanding or redeem or otherwise acquire any equity interest of such Acquired Subsidiary or right to any such equity interest; (iv) other than the current intercompany loans between Seller and the Retained Subsidiaries and the Acquired Subsidiaries, that would cause any Acquired Subsidiary to incur any indebtedness for borrowed money or to guaranty any obligations of any Person; or (v) that would be an amendment to any organizational documents of any Acquired Subsidiary.

  • Conduct of the Company’s Business The Company covenants and agrees that, prior to the Effective Time, unless Parent shall otherwise consent in writing or as otherwise expressly contemplated by this Agreement:

  • Conduct of the Company From the date hereof until the Effective Time, except as expressly contemplated by this Agreement, as set forth in Section 6.01 of the Company Disclosure Schedule, as consented to in writing by Parent, as contemplated by or reasonably necessary to implement the Company 50 Operating Plan (or, with respect to any initiative therein, reallocations among line items within such initiative that are not in the aggregate more burdensome to the Company in any material respect) or as required by Applicable Law, the Company shall, and shall cause each of its Subsidiaries to, conduct its business in all material respects in the ordinary course consistent with past practice and use its commercially reasonable efforts to (i) preserve intact its business organization, (ii) maintain in effect all of its material foreign, federal, state and local licenses, permits, consents, franchises, approvals and authorizations, and (iii) maintain its existing relationships with its material customers, lenders, suppliers and others having material business relationships with it and with Governmental Authorities with jurisdiction over the Company’s operations. Without limiting the generality of the foregoing, from the date hereof until the Effective Time, except as expressly contemplated by this Agreement, as set forth in Section 6.01 of the Company Disclosure Schedule, as consented to in writing by Parent (solely in the case of the following clauses (d), (e), (f), (g), (h), (i), (j) and (p), such consent not to be unreasonably withheld, conditioned or delayed), as contemplated by or reasonably necessary to implement the Company Operating Plan (or, with respect to any initiative therein, reallocations among line items within such initiative that are not in the aggregate more burdensome to the Company in any material respect) or as required by Applicable Law, the Company shall not, nor shall it permit any of its Subsidiaries to:

  • Conduct of the Arbitration 1. Where issues relating to jurisdiction or admissibility are raised as preliminary objections, the tribunal shall decide the matter before proceeding to the merits.

  • Conduct of Third Party Claims 11.4.1 If the matter or circumstance that may give rise to a claim against the Seller under this Agreement for breach of any Seller’s Warranty is a result of or in connection with a claim by a third party (a “Third Party Claim”) then:

  • CONDUCT OF THE AUCTION Conduct of the auction and increments of bidding are at the direction and discretion of the auctioneer. The seller and selling agents reserve the right to preclude any person from bidding if there is any question as to the person’s identity, credentials, fitness to bid, financial ability to buy, etc. All decisions of the Auctioneer are final. --- AGENCY DISCLOSURE & GENERAL OFFICE POLICIES: Ness Bros. will represent the Seller exclusively unless a Ness Bros. Agent has a signed buyer agency agreement with Buyer, then that agent has a limited agency with Buyer. --- DISCLAIMER & ABSENCE OF WARRANTIES: All information contained online or in the brochure and related material is subject to the terms and conditions outlined in the Purchase Agreement. The Property is being sold on an "AS IS, WHERE IS" basis. No warranty or representation, either expressed or implied, concerning the Property, its condition, or the condition of any other components on the Property, is made by the Seller or Ness Bros. All sketches and dimensions online or in the brochure are approximate. The information contained online or in the Brochure is subject to verification by all parties relying on it. No liability for its accuracy, errors, or omissions is assumed by the Seller or Ness Bros. Each potential bidder is responsible for conducting his or her own independent inspections, investigations, inquiries, and due diligence concerning the property. --- TERMS: Xxxxxxx Money of 10% down or $2,500.00, whichever is greater the day of Auction, balance is due in full upon delivery of the merchantable title and deed free and clear of all liens and encumbrances except as stated herein and subject to easements or restrictions of record. A Buyer’s Premium of 5%, or minimum of $2,500, whichever is greater will be added to final bid and included in the total contract price. All bids accepted on the Real Estate subject to Sellers approval.

  • Conduct of mediation In consultation with the mediator, the parties will determine a location, timetable and procedure for the mediation or, if the parties cannot agree on these matters within 7 Working Days of the appointment of the mediator these matters will be determined by the mediator.

  • Conduct of Hearing a. The formal rules of evidence do not apply, although the presiding officer will have discretion to exclude evidence that is incompetent, irrelevant, or cumulative, or the presentation of which will otherwise consume undue time.

Time is Money Join Law Insider Premium to draft better contracts faster.